Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel p...
Evogene (NASDAQ, TASE: EVGN) is a leading biote...
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a no...
Bicycle Therapeutics is a clinical-stage biopha...
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...
Provention Bio, Inc. is a clinical-stage biopha...
Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suff...
Marinus Pharmaceuticals, Inc. is committed to i...
Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company fo...
Amarin Corporation plc. is a rapidly growing, i...
With operations in South San Francisco, CA and Research Triangle Park, NC, Satsuma...
With operations in South San Francisco, CA and ...
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
Join the National Investor Network and get the latest information with your interests in mind.